Fate Therapeutics FATE

$2.04 +0.03 (1.49%)

Valuation

Market cap
249,228,000
Revenue TTM
$6,650,000
Net income TTM
$-136,320,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-2,049.92%
Debt to equity
0.00

Trading

Volume
876,200
Avg volume
1,350,220
Day's range
$2.01 – $2.12
Shares out
119,821,000
Stochastic %K
12%
Beta
2.52
Analysts
Moderate Buy
Price target
$5.74

Price

Company profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell progr...

Show more

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 875 1800
Website
https://www.fatetherapeutics.com
Address
12278 Scripps Summit Drive, San Diego, United States

Latest news

Stocktwits

StockDaddy68 Nov 3, 12:21 PM
$FATE I cast my "vote" for FATE!
0 replies
student56 Nov 2, 4:40 PM
$FATE holding. News should come in 5-6 nowember
0 replies
ChillGil Nov 2, 1:50 PM
$FATE Has a Major Phase 2 milestone.
0 replies
ChillGil Nov 2, 1:45 PM
$FATE 100% renal response in a small clinical cohort<
1 replies
radonco Nov 1, 7:09 PM
$FATE some interesting put options for Feb 2027 including $4 and $5 transacted for $20K and $30K and puts for May 2027 at $5 transacted for $32K
1 replies
Merlintrader Oct 31, 7:35 PM
$FATE closed the week at $2.08 (-1.4% w/w, -4.1% Friday), below the 50-day SMA ($2.29) and above the 200-day ($1.96). RSI14 45.3. Support $1.75, resistance $2.58 (20-day range, middle). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/fate-therapeutics-stock-hub/
0 replies
AlphaOfBiotech Oct 31, 3:09 PM
$FATE Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials, the unfortunate loss of its competitors, and the gain of $FATE , the king in autoimmune CAR-Ts will prove itself, long $FATE and wish us the best of luck 🤞🤞🤞$LABU 🤑🤑🤑
0 replies
Sebastjannxjcckckckvck Oct 31, 7:01 AM
$FATE Does FATE even have any competition left!??
0 replies